Dow Jones03-20 05:15
Health-care companies fell slightly amid ongoing doubt about the regulatory and earnings outlook for the sector.
Novo Nordisk said the U.S. Food and Drug Administration approved a higher dosage of its Wegovy weight-loss medication, a boost for the Danish drugmaker as it faces growing competition in the obesity market.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
March 19, 2026 17:15 ET (21:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
